• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK).

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Powles, T
    Brown, J
    Larkin, J
    Jones, R
    Ralph, C
    Hawkins, Robert E
    Chowdhury, S
    Boleti, E
    Bhal, A
    Fife, K
    Webb, A
    Crabb, S
    Geldart, T
    Hill, R
    Dunlop, J
    Hall, P
    McLaren, D
    Ackerman, C
    Beltran, L
    Nathan, P
    Show allShow less
    Affiliation
    The Royal Free NHS Foundation Trust, London, UK Barts Cancer Institute, CRUK Experiment Cancer Medicine Centre
    Issue Date
    2016-01-22
    
    Metadata
    Show full item record
    Abstract
    Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib.
    Citation
    A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK). 2016: Ann Oncol
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/603960
    DOI
    10.1093/annonc/mdw014
    PubMed ID
    26802156
    Type
    Article
    Language
    en
    ISSN
    1569-8041
    ae974a485f413a2113503eed53cd6c53
    10.1093/annonc/mdw014
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    • Authors: Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP
    • Issue date: 2012 Oct 10
    • Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
    • Authors: Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J
    • Issue date: 2012 Oct
    • Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    • Authors: Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E
    • Issue date: 2012 Oct 10
    • Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
    • Authors: Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, van Herpen CM, Mookerjee B, Pike L, Jürgensmeier JM, Gore ME
    • Issue date: 2012 Mar
    • Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
    • Authors: Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M, Hudson E, Reed N, Flubacher M, Jankowska P, Powell M, Dive C, West CML, Paul J
    • Issue date: 2015 Nov
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.